# Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT05168566** · PHASE2 · RECRUITING · sponsor: **Teligene US** · enrollment: 99 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Sutetinib Maleate Capsule

## Key facts

- **NCT ID:** NCT05168566
- **Lead sponsor:** Teligene US
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-01
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05168566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05168566, "Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05168566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*